RT Journal Article
SR Electronic
T1 A Whole Blood Molecular Signature for Acute Myocardial Infarction
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 045013
DO 10.1101/045013
A1 Evan D Muse
A1 Eric R Kramer
A1 Haiying Wang
A1 Paddy Barrett
A1 Fereshteh Parviz
A1 Mark A Novotny
A1 Roger S Lasken
A1 Timothy A Jatkoe
A1 Glenn Oliveira
A1 Hongfan Peng
A1 Jerry Lu
A1 Marc C Connelly
A1 Kurt Schilling
A1 Chandra Rao
A1 Ali Torkamani
A1 Eric J. Topol
YR 2016
UL http://biorxiv.org/content/early/2016/03/21/045013.abstract
AB Chest pain is a leading reason patients seek medical evaluation. While assays to detect myocyte death are used to diagnose a heart attack (acute myocardial infarction, AMI), there is no biomarker to indicate an impending cardiac event. Transcriptional patterns present in circulating endothelial cells (CEC) may provide a window into the plaque rupture process and identify a proximal biomarker for AMI. Thus, we aimed to identify a transcriptomic signature of AMI present in whole blood, but derived from CECs. Candidate genes indicative of AMI were nominated from microarray of enriched CEC samples, and then verified for detectability and predictive potential via qPCR in whole blood. This signature was validated in an independent cohort. Our findings suggest that a whole blood CEC-derived molecular signature identifies patients with AMI and sets the framework to potentially identify the earlier stages of an impending cardiac event where conventional biomarkers indicative of myonecrosis remain undetected.AMIacute myocardial infarctionAUCarea under the curveCADcoronary artery diseaseCECcirculating endothelial cellsCMPcirculating microparticlesCVDcardiovascular diseaseGSEAgene set enrichment analysisqPCRquantitative polymerase chain reactionROCreceiver operator characteristic